Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

LESSONS LEARNED: A biweekly TAS‐102 plus BEV schedule in patients with heavily pretreated mCRC showed equivalent efficacy with less toxicity compared with the current schedule of TAS‐102 plus BEV combination. Biweekly TAS‐102 plus BEV combination could reduce unnecessary dose reduction of TAS‐102, m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Satake, Hironaga, Kato, Takeshi, Oba, Koji, Kotaka, Masahito, Kagawa, Yoshinori, Yasui, Hisateru, Nakamura, Masato, Watanabe, Takanori, Matsumoto, Toshihiko, Kii, Takayuki, Terazawa, Tetsuji, Makiyama, Akitaka, Takano, Nao, Yokota, Mitsuru, Okita, Yoshihiro, Matoba, Koreatsu, Hasegawa, Hiroko, Tsuji, Akihito, Komatsu, Yoshito, Yoshino, Takayuki, Yamazaki, Kentaro, Mishima, Hideyuki, Oki, Eiji, Nagata, Naoki, Sakamoto, Junichi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8108052/
https://ncbi.nlm.nih.gov/pubmed/32666647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0643
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados